Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TANSTRIVE HARD CAPSULES 40MG - HSA Drug Approval Details

Approvals/HSA/TANSTRIVE HARD CAPSULES 40MG

Approved

THERAPEUTIC

TANSTRIVE HARD CAPSULES 40MG

Lilly del Caribe, Inc.Lilly, S.A. (Primary and Secondary Packager)🇸🇬 Health Sciences Authority

Approval Date: Apr 24, 2024
Approval ID: 062de784ca9c0de3
Company: Lilly del Caribe, Inc.Lilly, S.A. (Primary and Secondary Packager)
Type: Therapeutic

Approval Details

Approval Id: 062de784ca9c0de3
Drug Name: TANSTRIVE HARD CAPSULES 40MG
Product Name: TANSTRIVE HARD CAPSULES 40MG
Approval Number: SIN16990P
Approval Date: 2024-04-24
Registrant: DKSH SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: CAPSULE
Route Of Administration: ORAL
Atc Code: L01EX22
Atc Item Name: selpercatinib
Pharma Manufacturer Name: DKSH SINGAPORE PTE. LTD.
Company Detail Path: /organization/cbda6ad0d0b82155/dksh-singapore-pte-ltd

Active Ingredients

Selpercatinib

40.0mg

Selpercatinib

40.0mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Apr 24, 2024

Approval ID

062de784ca9c0de3

Type

Therapeutic

Back to HSA Approvals